Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other

Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products

By The Northwire Desk — AI Analysis Jan 27, 2026 · 10:01 NURL · 0.015 Neural Therapeutics Inc.
NURL · Price

Executive Summary

  • Neural Therapeutics announced that its portfolio company CWE European Holdings (Hanf.com) has received the first commercial shipments of Ritual Herbs products and begun sales in Germany.
  • The release provides an update on Neural’s strategic investment, noting completion of the first stage of a multi‑stage transaction whereby Neural now holds a 30.75% ownership interest in CWE.
  • Management highlights the large addressable market for nicotine‑free herbal cigarettes and cannabis‑related consumption in Germany, positioning Ritual Herbs as a growth catalyst for Hanf.com.

Key Details

  • Commercial Launch: CWE (Hanf.com) received its first commercial shipments of Ritual Herbs products; sales are now active across its retail, e‑commerce, and wholesale channels in Germany.
  • Distribution Rights: Hanf.com holds exclusive distribution rights for Ritual Herbs in the German market.
  • Market Opportunity: European nicotine‑free herbal cigarette market projected to exceed US$350 million by 2030; German cannabis use prevalence rose to 9.8% in 2024, with ~88.6% of consumption via smoking.
  • Addressable Consumer Base: Estimated >4.5 million potential consumers for Ritual Herbs blends in Germany.
  • Strategic Investment Progress:
  • May 26 2025 – Neural entered a Strategic Investment and Option Agreement with CWE, granting Neural the right to acquire up to 100% of CWE through multiple stages.
  • August 12 2025 – Completion of Stage 1: Neural acquired a 30.75% equity stake in CWE.
  • Future Transaction Plans: Neural and CWE will continue working toward subsequent acquisition stages; material updates will be provided as they occur.
  • Management Quote: Ronnie Jaegermann, CEO of CWE European Holdings, stated that the exclusive German distribution rights for Ritual Herbs “represent another meaningful growth catalyst” and reinforce Hanf.com’s competitive positioning in the legal CBD and cannabis market.

Notable Quotes

“Securing exclusive distribution rights in Germany for the Ritual Herbs product line represents another meaningful growth catalyst for Hanf.com,” – Ronnie Jaegermann, CEO, CWE European Holdings Inc.

All forward‑looking statements are subject to risks and uncertainties detailed in Neural Therapeutics’ continuous disclosure filings.

Read the original news release →

More from Neural Therapeutics Inc.

Jun 12, 2026 · 07:31

Neural Therapeutics Announces AGSM Results, CFO Appointment and Welcomes Positive Developments in the German Cannabis Market

M&A / Property May 19, 2026 · 07:31

Neural Therapeutics Retail Expansion Confirms Growth Trajectory Ahead of Critical M&A Vote

Production / Operations May 01, 2026 · 08:04

Neural Therapeutics Confirms Shareholder Vote for Hanf.com Acquisition Amidst Revenue Growth and Margin Compression

M&A / Property Mar 27, 2026 · 07:32

Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant

Financings Feb 19, 2026 · 08:54

Neural Therapeutics Announces CSE Application to Acquire Full Ownership of Hanf.com, Shareholder Meeting, SIO Agreement Amendment and Concurrent Financing

Technical Study Feb 10, 2026 · 07:31

Neural Portfolio Company Hanf.com Reports Strong Fiscal 2025 Results with 58% Revenue Growth and Positive Normalized Operating Income

Earnings